Ismael Samudio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1761382/publications.pdf

Version: 2024-02-01

46984 54882 7,927 99 47 84 citations h-index g-index papers 101 101 101 11523 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Induction of Durable Antitumor Response by a Novel Oncolytic Herpesvirus Expressing Multiple Immunomodulatory Transgenes. Biomedicines, 2020, 8, 484.	1.4	28
2	Oncolytic virotherapy in hepatoâ€bilioâ€pancreatic cancer: The key to breaking the log jam?. Cancer Medicine, 2020, 9, 2943-2959.	1.3	12
3	UV Light–inactivated HSV-1 Stimulates Natural Killer Cell–induced Killing of Prostate Cancer Cells. Journal of Immunotherapy, 2019, 42, 162-174.	1.2	5
4	Cell-surface proteomics for the identification of novel therapeutic targets in cancer. Expert Review of Proteomics, 2018, 15, 259-275.	1.3	51
5	High-throughput profiling of signaling networks identifies mechanism-based combination therapy to eliminate microenvironmental resistance in acute myeloid leukemia. Haematologica, 2017, 102, 1537-1548.	1.7	14
6	The mitochondria target drug avocatin B synergizes with induction chemotherapeutics to induce leukemia cell death. Leukemia and Lymphoma, 2017, 58, 986-988.	0.6	21
7	DMSO Represses Inflammatory Cytokine Production from Human Blood Cells and Reduces Autoimmune Arthritis. PLoS ONE, 2016, 11, e0152538.	1.1	65
8	All Trans Retinoic Acid, Transforming Growth Factor \hat{I}^2 and Prostaglandin E2 in Mouse Plasma Synergize with Basophil-Secreted Interleukin-4 to M2 Polarize Murine Macrophages. PLoS ONE, 2016, 11, e0168072.	1.1	20
9	Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes. Oncotarget, 2016, 7, 79722-79735.	0.8	133
10	UV-inactivated HSV-1 potently activates NK cell killing of leukemic cells. Blood, 2016, 127, 2575-2586.	0.6	28
11	Biguanides sensitize leukemia cells to ABT-737-induced apoptosis by inhibiting mitochondrial electron transport. Oncotarget, 2016, 7, 51435-51449.	0.8	33
12	Targeting leukemia's "fatty tooth― Blood, 2015, 126, 1874-1875.	0.6	20
13	The cell cycle regulator $14-3-3\ddot{l}f$ opposes and reverses cancer metabolic reprogramming. Nature Communications, 2015, 6, 7530.	5.8	65
14	Mapping Microenvironment-Mediated Signaling Dependency of Targeted Inhibitors: A Mechanism-Based Approach of Selecting Effective Therapy Targeting Drug Resistant AML. Blood, 2015, 126, 1398-1398.	0.6	0
15	Paracrine factors of human mesenchymal stem cells increase wound closure and reduce reactive oxygen species production in a traumatic brain injury in vitro model. Human and Experimental Toxicology, 2014, 33, 673-684.	1.1	52
16	Tratamiento de rescate de leucemia aguda refractaria o en recaÃda con el régimen IDA-FLAC: experiencia en la rutina de los servicios. Revista Colombiana De CancerologÃa, 2014, 18, 53-61.	0.0	6
17	A low carbohydrate, high protein diet combined with celecoxib markedly reduces metastasis. Carcinogenesis, 2014, 35, 2291-2299.	1.3	16
18	Platelets Promote Mitochondrial Uncoupling and Resistance to Apoptosis in Leukemia Cells: A Novel Paradigm for the Bone Marrow Microenvironment. Cancer Microenvironment, 2014, 7, 79-90.	3.1	28

#	Article	IF	CITATIONS
19	Bone Marrow Adipocyte-Derived Free Fatty Acids Induce Gene Signature Linking Transcription with Metabolic Changes That Contribute to Survival of Acute Monocytic Leukemia Cells. Blood, 2014, 124, 1013-1013.	0.6	O
20	Tumor stroma engraftment of gene-modified mesenchymal stem cells as anti-tumor therapy against ovarian cancer. Cytotherapy, 2013, 15, 20-32.e2.	0.3	59
21	Autologous Platelet Concentrates as an Adjunctive Treatment for Chronic Laminitis in a Mare with Pituitary Pars Intermedia Dysfunction. Journal of Equine Veterinary Science, 2013, 33, 191-195.	0.4	10
22	HDAC inhibition by SNDX-275 (Entinostat) restores expression of silenced leukemia-associated transcription factors Nur77 and Nor1 and of key pro-apoptotic proteins in AML. Leukemia, 2013, 27, 1358-1368.	3.3	50
23	Metformin inhibits pancreatic cancer cell and tumor growth and downregulates Sp transcription factors. Carcinogenesis, 2013, 34, 2870-2879.	1.3	89
24	Mitochondrial Uncoupling and the Reprograming of Intermediary Metabolism in Leukemia Cells. Frontiers in Oncology, 2013, 3, 67.	1.3	37
25	Asparaginase unveils glutamine-addicted AML. Blood, 2013, 122, 3398-3400.	0.6	20
26	Mecanismos antitumorales de la metformina: se $\tilde{A}\pm a$ lizaci \tilde{A}^3 n, metabolismo, inmunidad y m \tilde{A}_i s all \tilde{A}_i Universitas Scientiarum, 2013, 15, 122.	0.2	3
27	Unraveling The Molecular and Metabolic Basis For Glutamine Addiction In Leukemias. Blood, 2013, 122, 606-606.	0.6	O
28	Cellular and molecular mechanisms of antioxidants in Parkinson's disease. Nutritional Neuroscience, 2012, 15, 120-126.	1.5	102
29	Effects of natural antioxidants in neurodegenerative disease. Nutritional Neuroscience, 2012, 15, 1-9.	1.5	222
30	Metformin as a Novel Component of Metronomic Chemotherapeutic Use: A Hypothesis. Journal of Experimental and Clinical Medicine, 2012, 4, 140-144.	0.2	5
31	Regulation of HIF- $\hat{\Pi}\pm$ signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment. Cancer Biology and Therapy, 2012, 13, 858-870.	1.5	119
32	Suppression of Mir-93 May Regulate Anti-Oxidant Metabolism in Mesenchymal Stromal Cells Derived From Acute Myeloid Leukemia Patients Blood, 2012, 120, 2354-2354.	0.6	0
33	In vitro bactericidal activity of equine platelet concentrates, platelet poor plasma, and plasma against methicillin-resistant Staphylococcus aureus. Archivos De Medicina Veterinaria, 2011, 43, 155-161.	0.2	30
34	Physiological hypoxia promotes lipid raft and PI3K-dependent activation of MAPK 42/44 in leukemia cells. Leukemia, 2010, 24, 1364-1367.	3.3	19
35	Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. Journal of Clinical Investigation, 2010, 120, 142-156.	3.9	572
36	Methyl 2-Cyano-3,12-dioxooleana-1,9-dien-28-oate Decreases Specificity Protein Transcription Factors and Inhibits Pancreatic Tumor Growth: Role of MicroRNA-27a. Molecular Pharmacology, 2010, 78, 226-236.	1.0	92

3

#	Article	IF	Citations
37	Mesenchymal stromal cells alone or expressing interferon- $\hat{1}^2$ suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment. Cytotherapy, 2010, 12, 615-625.	0.3	166
38	Activation of p53 signaling by MI-63 induces apoptosis in acute myeloid leukemia cells. Leukemia and Lymphoma, 2010, 51, 911-919.	0.6	15
39	Apoptosis in Leukemias: Regulation and Therapeutic Targeting. Cancer Treatment and Research, 2009, 145, 197-217.	0.2	15
40	Mitochondrial Uncoupling and the Warburg Effect: Molecular Basis for the Reprogramming of Cancer Cell Metabolism. Cancer Research, 2009, 69, 2163-2166.	0.4	280
41	Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood, 2009, 113, 6215-6224.	0.6	467
42	CXCR4 expression and biologic activity in acute myeloid leukemia are dependent on oxygen partial pressure. Blood, 2009, 113, 1504-1512.	0.6	123
43	Pharmacological Inhibition of Fatty Acid Oxidation as a Novel Therapeutic Concept for Acute Myeloid Leukemia Blood, 2009, 114, 3779-3779.	0.6	0
44	1,1â€bis(3′â€indolyl)â€1â€(<i>pâ€</i> substituted phenyl)methanes decrease mitochondrial membrane potentinduce apoptosis in endometrial and other cancer cell lines. Molecular Carcinogenesis, 2008, 47, 492-507.	tial and 1.3	23
45	The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML. Leukemia, 2008, 22, 1728-1736.	3.3	106
46	Mechanisms of Antileukemic Activity of the Novel Bcl-2 Homology Domain-3 Mimetic GX15-070 (Obatoclax). Cancer Research, 2008, 68, 3413-3420.	0.4	254
47	The Warburg Effect in Leukemia-Stroma Cocultures Is Mediated by Mitochondrial Uncoupling Associated with Uncoupling Protein 2 Activation. Cancer Research, 2008, 68, 5198-5205.	0.4	153
48	Inhibition of mitochondrial metabolism by methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate induces apoptotic or autophagic cell death in chronic myeloid leukemia cells. Molecular Cancer Therapeutics, 2008, 7, 1130-1139.	1.9	50
49	Targeting Anaplerotic Pathways That Support Fatty Acid Metabolism as a Therapeutic Strategy for Hematological Malignancies: The Achilles' Heel of the Warburg Effect Blood, 2008, 112, 1631-1631.	0.6	O
50	Mitogen-Activated Protein Kinase Kinase Inhibition Enhances Nuclear Proapoptotic Function of p53 in Acute Myelogenous Leukemia Cells. Cancer Research, 2007, 67, 3210-3219.	0.4	50
51	Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood, 2007, 109, 3509-3512.	0.6	318
52	Synergistic Induction of Apoptosis by Simultaneous Disruption of the Bcl-2 and mTOR/Akt Pathways in Acute Myeloid Leukemia Blood, 2007, 110, 1588-1588.	0.6	0
53	The Hypoxic Microenvironment in Acute Myelogenous Leukemia: Critical Role of CXCR4 in the Induction of HIF- $1\hat{1}\pm$ Blood, 2007, 110, 1819-1819.	0.6	O
54	Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. Molecular Cancer Therapeutics, 2006, 5, 3113-3121.	1.9	183

#	Article	IF	CITATIONS
55	3,3′-Diindolylmethane (DIM) and its derivatives induce apoptosis in pancreatic cancer cells through endoplasmic reticulum stress-dependent upregulation of DR5. Carcinogenesis, 2006, 27, 717-728.	1.3	190
56	Concomitant Inhibition of MDM2 and Bcl-2 Protein Function Synergistically Induce Mitochondrial Apoptosis in AML. Cell Cycle, 2006, 5, 2778-2786.	1.3	91
57	Inhibition of breast cancer cell growth and induction of cell death by 1,1-bis($3\hat{a}\in^2$ -indolyl)methane (DIM) and 5,5 $\hat{a}\in^2$ -dibromoDIM. Cancer Letters, 2006, 236, 198-212.	3.2	22
58	Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell, 2006, 10, 375-388.	7.7	921
59	Simultaneous Inhibition of PDK1/AKT and Fms-Like Tyrosine Kinase 3 Signaling by a Small-Molecule KP372-1 Induces Mitochondrial Dysfunction and Apoptosis in Acute Myelogenous Leukemia. Cancer Research, 2006, 66, 3737-3746.	0.4	101
60	A Novel Mechanism of Action of Methyl-2-cyano-3,12 Dioxoolean-1,9 Diene-28-oate: Direct Permeabilization of the Inner Mitochondrial Membrane to Inhibit Electron Transport and Induce Apoptosis. Molecular Pharmacology, 2006, 69, 1182-1193.	1.0	56
61	Rapamycin Analogs Reduce mTORC2 Signaling and Inhibit AKT Activation in AML Blood, 2006, 108, 156-156.	0.6	2
62	Relationship between mTOR-Mediated Upregulation of Glycolysis and Chemosensitivity of ALL Blasts Blood, 2006, 108, 1833-1833.	0.6	1
63	Inhibition of Bcl-2 Signaling by Small Molecule BH3 Inhhibitor GX15-070 as a Novel Therapeutic Strategy in AML Blood, 2006, 108, 2584-2584.	0.6	0
64	Novel Small Molecule MDM2 Inhibitor MI-63 Induces p53-Dependent Apoptosis in AML Cell Lines Blood, 2006, 108, 2596-2596.	0.6	3
65	Guggulsterones induce apoptosis and differentiation in acute myeloid leukemia: identification of isomer-specific antileukemic activities of the pregnadienedione structure. Molecular Cancer Therapeutics, 2005, 4, 1982-1992.	1.9	60
66	2-Cyano-3,12-dioxoolean-1,9-dien-28-oic Acid and Related Compounds Inhibit Growth of Colon Cancer Cells through Peroxisome Proliferator-Activated Receptor \hat{I}^3 -Dependent and -Independent Pathways. Molecular Pharmacology, 2005, 68, 119-128.	1.0	83
67	2-Cyano-3,12-dioxooleana-1,9-dien-28-imidazolide (CDDO-Im) Directly Targets Mitochondrial Glutathione to Induce Apoptosis in Pancreatic Cancer. Journal of Biological Chemistry, 2005, 280, 36273-36282.	1.6	100
68	Inhibition of Tumor-Necrosis-Factor-αDELETEInduced Endothelial Cell Activation by a New Class of PPAR-Î ³ Agonists. Journal of Vascular Research, 2005, 42, 509-516.	0.6	20
69	A Novel Ring-Substituted Diindolylmethane,1,1-Bis[3′-(5-Methoxyindolyl)]-1-(p-t-Butylphenyl) Methane, Inhibits Extracellular Signal-Regulated Kinase Activation and Induces Apoptosis in Acute Myelogenous Leukemia. Cancer Research, 2005, 65, 2890-2898.	0.4	116
70	Inhibition of Bcl-2 Signaling by Small Molecule BH3 Inhibitor GX15-070 as a Novel Therapeutic Strategy in AML Blood, 2005, 106, 3372-3372.	0.6	1
71	Mechanisms of Apoptosis Induction by BH3 Inhibitor ABT-737 in AML Blood, 2005, 106, 244-244.	0.6	0
72	Guggulsterones Induce Apoptosis and Differentiation in AML: Identification of Isomer-Specific Antileukemic Activities of the Pregnanedienedione Structure Blood, 2005, 106, 4466-4466.	0.6	0

#	Article	IF	Citations
73	Relationship between m-TOR-Mediated Upregulation of Glycolysis, Chemoresistance, and Prognosis in Patients with ALL Blood, 2005, 106, 12-12.	0.6	2
74	Mechanisms and Activity of PPARÎ ³ -Active Triterpenoids CDDO and CDDO-Me in Leukemias Blood, 2005, 106, 2460-2460.	0.6	0
75	A Novel Mechanism of Action of Methyl-2-cyano-3,12 dioxoolean-1,9 diene-28-oate (CDDO-Me): Direct Permeabilization of the Inner Mitochondrial Membrane To Inhibit Electron Transport and Induce Apoptosis Blood, 2005, 106, 4462-4462.	0.6	0
76	Peroxisome Proliferator-Activated Receptor \hat{I}^3 -Dependent Activation of p21 in Panc-28 Pancreatic Cancer Cells Involves Sp1 and Sp4 Proteins. Endocrinology, 2004, 145, 5774-5785.	1.4	73
77	Resistin Promotes Smooth Muscle Cell Proliferation Through Activation of Extracellular Signal–Regulated Kinase 1/2 and Phosphatidylinositol 3-Kinase Pathways. Circulation, 2004, 110, 3335-3340.	1.6	291
78	Estrogen regulation of vascular endothelial growth factor gene expression in ZR-75 breast cancer cells through interaction of estrogen receptor \hat{l}_{\pm} and SP proteins. Oncogene, 2004, 23, 1052-1063.	2.6	127
79	Estrogen-dependent regulation of ornithine decarboxylase in breast cancer cells through activation of nongenomic cAMP-dependent pathways. Molecular Carcinogenesis, 2004, 40, 160-170.	1.3	31
80	1,1-Bis($3\hat{a}\in^2$ -indolyl)-1-(p-substitutedphenyl)methanes Induce Peroxisome Proliferator-Activated Receptor \hat{I}^3 -Mediated Growth Inhibition, Transactivation, and Differentiation Markers in Colon Cancer Cells. Cancer Research, 2004, 64, 5994-6001.	0.4	69
81	ARTS, a Pro-Apoptotic Mitochondrial Septin-Like Protein That Binds to XIAP, Is Silenced in Acute Lymphoblastic and Primitive Acute Myeloblastic Leukemia Cells Blood, 2004, 104, 3378-3378.	0.6	9
82	A Novel Ring-Substituted Diindolylmethane 1,1-bis [3′-(5-methoxyindolyl)]-1-(p-t-butylphenyl) Methane Abrogates ERK Activation and Induces Apoptosis in Acute Myeloid Leukemia (AML) Blood, 2004, 104, 3399-3399.	0.6	0
83	A new class of peroxisome proliferator-activated receptor gamma (PPARgamma) agonists that inhibit growth of breast cancer cells: 1,1-Bis(3'-indolyl)-1-(p-substituted phenyl)methanes. Molecular Cancer Therapeutics, 2004, 3, 247-60.	1.9	55
84	Estrogen Receptor/Sp1 Complexes Are Required for Induction ofcadGene Expression by 17β-Estradiol in Breast Cancer Cells. Endocrinology, 2003, 144, 2325-2335.	1.4	83
85	Small Inhibitory RNA Duplexes for Sp1 mRNA Block Basal and Estrogen-induced Gene Expression and Cell Cycle Progression in MCF-7 Breast Cancer Cells. Journal of Biological Chemistry, 2002, 277, 28815-28822.	1.6	107
86	Cooperative Coactivation of Estrogen Receptor \hat{l}_{\pm} in ZR-75 Human Breast Cancer Cells by SNURF and TATA-binding Protein. Journal of Biological Chemistry, 2002, 277, 2485-2497.	1.6	38
87	Estrogen Up-Regulation of p53 Gene Expression in MCF-7 Breast Cancer Cells Is Mediated by Calmodulin Kinase IV-Dependent Activation of a Nuclear Factor ÎB/CCAAT-Binding Transcription Factor-1 Complex. Molecular Endocrinology, 2002, 16, 1793-1809.	3.7	54
88	Transcriptional activation of rat creatine kinase B by 17?-estradiol in MCF-7 cells involves an estrogen responsive element and GC-rich sites. Journal of Cellular Biochemistry, 2002, 84, 156-172.	1.2	23
89	Transcriptional activation of cathepsin D gene expression by $17\hat{l}^2$ -estradiol: mechanism of aryl hydrocarbon receptor-mediated inhibition. Molecular and Cellular Endocrinology, 2001, 172, 91-103.	1.6	76
90	Estrogen Regulation of Cyclin D1 Gene Expression in ZR-75 Breast Cancer Cells Involves Multiple Enhancer Elements. Journal of Biological Chemistry, 2001, 276, 30853-30861.	1.6	176

#	Article	IF	CITATIONS
91	Transcriptional Activation of Deoxyribonucleic Acid Polymerase \hat{l}_{\pm} Gene Expression in MCF-7 Cells by $17\hat{l}^2$ -Estradiol*. Endocrinology, 2001, 142, 1000-1008.	1.4	34
92	Transcriptional Activation of Deoxyribonucleic Acid Polymerase Gene Expression in MCF-7 Cells by 17Â-Estradiol. Endocrinology, 2001, 142, 1000-1008.	1.4	16
93	Mechanisms of inhibitory aryl hydrocarbon receptor-estrogen receptor crosstalk in human breast cancer cells. Journal of Mammary Gland Biology and Neoplasia, 2000, 5, 295-306.	1.0	147
94	Transcriptional Activation of Thymidylate Synthase by $17\hat{l}^2$ -Estradiol in MCF-7 Human Breast Cancer Cells*. Endocrinology, 2000, 141, 2439-2449.	1.4	34
95	Transcriptional activation of transforming growth factor alpha by estradiol: requirement for both a GC-rich site and an estrogen response element half-site. Journal of Molecular Endocrinology, 2000, 24, 329-338.	1.1	73
96	Inhibition of Vascular Endothelial Growth Factor Expression in HEC1A Endometrial Cancer Cells through Interactions of Estrogen Receptor \hat{l}_{\pm} and Sp3 Proteins. Journal of Biological Chemistry, 2000, 275, 22769-22779.	1.6	75
97	Transcriptional Activation of c-fos Protooncogene by $17\hat{l}^2$ -Estradiol: Mechanism of Aryl Hydrocarbon Receptor-Mediated Inhibition. Molecular Endocrinology, 1999, 13, 1511-1521.	3.7	99
98	Mechanisms of Transcriptional Activation of bcl-2 Gene Expression by $17\hat{l}^2$ -Estradiol in Breast Cancer Cells. Journal of Biological Chemistry, 1999, 274, 32099-32107.	1.6	230
99	Transcriptional Activation of Thymidylate Synthase by $17\hat{l}^2$ -Estradiol in MCF-7 Human Breast Cancer Cells. , 0, .		9